Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States.
Flawless balance sheet and overvalued.
Share Price & News
How has Atara Biotherapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ATRA's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: ATRA underperformed the US Biotechs industry which returned 23.4% over the past year.
Return vs Market: ATRA underperformed the US Market which returned 7.1% over the past year.
Price Volatility Vs. Market
How volatile is Atara Biotherapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 months ago | Simply Wall StHere's Why We're Watching Atara Biotherapeutics's (NASDAQ:ATRA) Cash Burn Situation
6 months ago | Simply Wall StHere's Why Atara Biotherapeutics (NASDAQ:ATRA) Must Use Its Cash Wisely
8 months ago | Simply Wall StHave Insiders Been Selling Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares?
Is Atara Biotherapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: ATRA ($11.13) is trading above our estimate of fair value ($11.07)
Significantly Below Fair Value: ATRA is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ATRA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: ATRA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ATRA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ATRA is good value based on its PB Ratio (2.6x) compared to the US Biotechs industry average (3.7x).
How is Atara Biotherapeutics forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ATRA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ATRA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ATRA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if ATRA's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if ATRA's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ATRA's Return on Equity is forecast to be high in 3 years time
How has Atara Biotherapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ATRA is currently unprofitable.
Growing Profit Margin: ATRA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ATRA is unprofitable, and losses have increased over the past 5 years at a rate of -40.6% per year.
Accelerating Growth: Unable to compare ATRA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ATRA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: ATRA has a negative Return on Equity (-117.96%), as it is currently unprofitable.
How is Atara Biotherapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: ATRA's short term assets ($229.2M) exceed its short term liabilities ($31.5M).
Long Term Liabilities: ATRA's short term assets ($229.2M) exceed its long term liabilities ($15.2M).
Debt to Equity History and Analysis
Debt Level: ATRA is debt free.
Reducing Debt: ATRA had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ATRA has sufficient cash runway for 11 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: ATRA is forecast to have sufficient cash runway for 10 months based on free cash flow estimates, but has since raised additional capital.
What is Atara Biotherapeutics's current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ATRA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ATRA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ATRA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ATRA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ATRA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Pascal Touchon (56yo)
Mr. Pascal Touchon has been President, Chief Executive Officer and Director at Atara Biotherapeutics, Inc. since June 24, 2019 and joined it in June 2019. He serves as Director of Cogen Therapeutics, Inc. ...
CEO Compensation Analysis
Compensation vs Market: Pascal's total compensation ($USD6.87M) is above average for companies of similar size in the US market ($USD3.13M).
Compensation vs Earnings: Insufficient data to compare Pascal's compensation with company performance.
|Senior VP & CFO||1.92yrs||US$2.54m||0.039% $312.6k|
|Executive VP & COO||0.25yr||US$2.72m||0.032% $251.0k|
|Head of Investor Relations & Finance||no data||no data||no data|
|Senior VP & General Counsel||0.083yr||no data||no data|
|Head of Corporate Communications||no data||no data||no data|
|Senior Vice President of Global Human Resources||3.75yrs||no data||no data|
|Senior VP & Chief Medical Officer||no data||no data||no data|
|Senior Vice President of Quality Assurance & Process Sciences||1.75yrs||no data||no data|
|Senior Vice President of Global Regulatory Affairs||1.67yrs||no data||no data|
Experienced Management: ATRA's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
|Independent Director||7.75yrs||US$302.49k||0.026% $210.6k|
|Independent Director||5.17yrs||US$327.49k||0.027% $216.2k|
|Independent Director||4.5yrs||US$302.49k||0.014% $114.9k|
|Independent Director||6.17yrs||US$317.49k||0.037% $295.4k|
|Non-Executive Chairman||0.083yr||no data||no data|
|Lead Independent Director||no data||US$332.49k||0.15% $1.2m|
|Independent Director||1.67yrs||US$293.62k||no data|
|Director||no data||no data||no data|
Experienced Board: ATRA's board of directors are considered experienced (4.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 54.5%.
Atara Biotherapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Atara Biotherapeutics, Inc.
- Ticker: ATRA
- Exchange: NasdaqGS
- Founded: 2012
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$796.742m
- Shares outstanding: 71.59m
- Website: https://www.atarabio.com
Number of Employees
- Atara Biotherapeutics, Inc.
- 611 Gateway Boulevard
- Suite 900
- South San Francisco
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ATRA||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Oct 2014|
|AT2||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Oct 2014|
|0HIY||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Oct 2014|
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, and autoimmune and viral diseases, including ATA2271 for mesothelin; ATA2321 for acute myeloid leukemia; and ATA2431 and ATA3219 for B-cell lymphomas, as well as ATA188 and ATA190 that are in Phase I clinical trials for the treatment of multiple sclerosis. In addition, it is developing ATA621 against the BK and JC viruses; ATA368 for patients with human papillomavirus and associated cancers; ATA520 to treat Wilms tumor 1; and ATA230 against cytomegalovirus and related diseases. The company has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in South San Francisco, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/28 06:40|
|End of Day Share Price||2020/05/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.